MYOGENIN is a member of the muscle regulatory factor family that orchestrates an obligatory step in myogenesis, the terminal differentiation of skeletal muscle cells. A paradoxical feature of alveolar rhabdomyosarcoma (ARMS), a prevalent soft tissue sarcoma in children arising from cells with a myogenic phenotype, is the inability of these cells to undergo terminal differentiation despite the expression of MYOGENIN. The chimeric PAX3-FOXO1 fusion protein which results from a chromosomal translocation in ARMS has been implicated in blocking cell cycle arrest, preventing myogenesis from occurring. We report here that PAX3-FOXO1 enhances glycogen synthase kinase 3b (GSK3b) activity which in turn represses MYOGENIN activity. MYOGENIN is a GSK3b substrate in vitro on the basis of in vitro kinase assays and MYOGENIN is phosphorylated in ARMS-derived RH30 cells. Constitutively active GSK3b(S9A) increased the level of a phosphorylated form of MYOGENIN on the basis of western blot analysis and this effect was reversed by neutralization of the single consensus GSK3b phosphoacceptor site by mutation (S160/164A). Congruently, GSK3b inhibited the trans-activation of an E-box reporter gene by wild-type MYOGENIN, but not MYOGENIN with the S160/164A mutations. Functionally, GSK3b repressed muscle creatine kinase (MCK) promoter activity, an effect which was reversed by the S160/164A mutated MYOGENIN. Importantly, GSK3b inhibition or exogenous expression of the S160/164A mutated MYOGENIN in ARMS reduced the anchorage independent growth of RH30 cells in colony-formation assays. Thus, sustained GSK3b activity represses a critical regulatory step in the myogenic cascade, contributing to the undifferentiated, proliferative phenotype in alveolar rhabdomyosarcoma (ARMS).
Subject Category: Cancer Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma, accounting for 5% of all childhood cancers and approximately 50% of soft tissue sarcomas. [1] [2] [3] There are two main subtypes: embryonal and alveolar RMS and although embryonal RMS is more common, alveolar RMS is considered to carry a worse prognosis. A gene fusion resulting in the t(2;13)(q35;q14) somatic cell chromosomal translocation fuses PAX3 and Foxo1 to create a potent transcription factor (PAX3-FOXO1) which is a predominant causative genetic lesion for the development of alveolar rhabdomyosarcoma (ARMS). 1 ARMS is a highly malignant mesenchymal tumor that has properties of immature striated muscle tissue resulting in dense aggregates of poorly differentiated cells that are separated by fibrous membranes resulting in a loss in cellular cohesion. 2, 3 PAX3 is a key determinant of somatic myogenesis and, is involved in the migration of progenitor cells to the dermomyotome region of the somite where they grow and divide in the presence of growth factors. 4 PAX3 is also required to activate the myogenic determination gene, MYOD.
5 MYOD is one of four myogenic regulatory factors (MRFs, which include MYF-5, MRF4 and MYOGENIN) from the basic helix-loop-helix superfamily of transcription factors which interact with myocyte enhancer factor-2 (MEF2) proteins in the hierarchical control of muscle-specific gene expression. 6 Two kinases that potently exert effects on this myogenic regulatory cascade are p38 mitogen activated protein kinase (MAPK) and glycogen synthase kinase 3b (GSK3b). p38 MAPK is a key regulator of skeletal myogenesis that critically interacts with and activates MEF2 in the somite myotome during development. [7] [8] [9] Conversely, GSK3b activation leads to a repression in skeletal and cardiac muscle differentiation, in part by antagonizing p38 MAPK-mediated activation of MEF2. 10, 11 GSK3b usually targets proteins that have already been phosphorylated by another kinase at a 'priming' serine or threonine residue located four amino acids C-terminal to a consensus (S/T)XXX(S/T)-PO 4 motif. 12, 13 Regulation of MEF2 and the MRFs leads to morphological changes including epithelial to mesenchymal transition, cell alignment and fusion to form multinucleated myotubes that eventually develop into functional, contractile muscle fibers. In particular, cells that express MYOD and MYOGENIN are typically fusion competent 14, 15 with the exception of ARMS cell types. To date, lack of myogenic differentiation of PAX3-FOXO1 expressing ARMS cells has been attributed to their inability to upregulate p57
Kip2 activity, hence destabilizing the DNA binding affinity of MYOD transcription complexes. 16 Dysfunctional MYOD/Eprotein complex association and transcriptional control is a common feature between ARMS and the non-PAX3-FOXO1 expressing embryonal rhabdomyosarcoma (ERMS). Subsequent restoration of the MYOD/E12 complex has been shown to switch ERMS cells from an arrested myofibroblast phase to a more differentiated state. 17 Similarly p38 MAPK activity can potentiate myogenic differentiation in ERMS cells by enhancing MYOD trans-activation properties. 18 Therefore, it is fairly clear that in both rhabdomyosarcoma subtypes the ability of MYOD to potentiate transcription is compromised. However, the role of MYOGENIN in RMS is more equivocal. For normal myogenesis to occur, both in vitro and in vivo, an absolute requirement for MYOGENIN is evident. Thus, MYOGENIN activity constitutes a pivot point for irreversible commitment to terminal differentiation. 19, 20 The combination of data from gene targeting studies of the MRFs 21, 22 supports the prevailing consensus that while the other three MRFs can compensate each other's functional roles, [23] [24] [25] [26] MYOGENIN is absolutely essential for skeletal muscle fiber formation. 20 Despite its expression in RMS, the paradox as to why MYOGENIN cannot mediate competence for differentiation is unknown.
Here, we examined the posttranslational regulation of MYOGENIN in ARMS. On the basis of the in silico prediction of a single consensus phosphorylation site for GSK3b on the MYOGENIN protein and also high levels of GSK3b activity in these cells, we determined that MYOGENIN function is potently repressed by GSK3b activity in ARMS. Moreover, pharmacological inhibition of GSK3b results in a profound decrease in size and, to a certain extent, number of RMS colonies in a colony-formation assay. This effect is mimicked by introduction of MYOGENIN bearing neutralizing mutations in the GSK3b consensus site. In combination, these data reveal MYOGENIN as a key target of GSK3b activity in Cell Type  RH30  C2C12  Condition  DM  Time (days)  1 2 4  4  ± PAX3-FOXO1   PAX3-FOXO1   PAX3   MYF5   MYOD   MEF2A   MYOGENIN   ACTIN   97kDa   55kDa   32kDa   38kDa   62kDa   30kDa   43kDa   4  1  1 
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Actin pS9-GSK3β RH30 RD Figure 1 MYOGENIN protein expression and GSK3b activity are both maintained in ARMS: (a) C2C12 myoblasts were transfected with HA-PAX3-FOXO1 or pcDNA3.1 control plasmid for 1 day before extraction or serum withdrawal and then extraction at 1 day increments for up to 4 days as indicated. Protein levels were compared with protein extracts from PAX3-FOXO1 expressing RH30 cells 1 day in growth media (GM) and 4 days in differentiation media (DM (Figure 1a ). In addition, PAX3-FOXO1 repressed myotube formation in C2C12 myoblasts (Figures 1a and b) . Detection of myogenic differentiation using an MCK promoter driving GFP expression 27 revealed GFP expressing, multinucleated myotubes in the controls but not in cells expressing PAX3-FOXO1 (Figure 1b) .
It is well documented that MRFs and MEF2 proteins are highly sensitive to pro-myogenic kinases such as p38 MAPK 9, [28] [29] [30] and also kinases such as GSK3b which are 10,31 Therefore we tested for GSK3b activity under conditions when myogenesis is supressed. As GSK3b is constitutively active until it is repressed by phosphorylation at serine 9 (by PKB), we assessed both total GSK3b protein expression levels and S9 phosphorylation levels using appropriate antibodies as indicated. We document that GSK3b is expressed in proliferative C2C12 myoblasts, PAX3-FOXO1 expressing ARMS cells (RH30) and, non-PAX3-FOXO1 ERMS cells (RD). However only in PAX3-FOXO1 expressing RH30 cells, is GSK3b predominantly in its unphosphorylated form (at serine 9) and, hence fully active state ( Figure 1c ). In addition, ectopic expression of PAX3-FOXO1 resulted in reduced phosphorylation of GSK3b at serine 9 in C2C12 myoblasts ( Figure 1d ).
MYOGENIN trans-activation function is repressed by GSK3b. To assess the effect of GSK3b activity on MYO-GENIN function, trans-activation of a 4x E-box Luciferase construct was measured in proliferating C2C12 myoblasts that were transfected with different combinations of constitutively active GSK3b(S9A) and MYOGENIN as indicated in GSK3b directly phosphorylates MYOGENIN in vitro. In order to determine whether MYOGENIN is a substrate for GSK3b, an in vitro kinase assay was performed using GST-MYOGENIN (1-225), purified GST-GSK3b and g-32 P ATP. Bands were resolved using SDS-PAGE and subsequent autoradiography showed 32 P labeled bands for MYOGENIN, autophosphorylated GSK3b and MyBP (positive control, Figure 2b ). In addition, Coomassie Blue staining revealed a lower mobility band indicative of phosphorylation ( Figure 2b ). To further test the idea that the lower mobility band is hyperphosphorylated, we used calf-intestinal phosphatases on RH30 cell lysates and found that the low mobility band was eradicated (Figure 2c ). Collectively these data suggest that MYOGENIN is a GSK3b substrate in vitro.
Pharmacologic manipulation of GSK3b activity alters MYOGENIN properties. To further investigate the effect of GSK3b on MYOGENIN, COS7 cells were co-transfected with MYOGENIN and GSK3b(S9A) and, then treated with or without 10 mM GSK3b inhibitor, AR-A014418, as indicated in Figures 3a and b . Western blot analysis revealed two predominant forms of MYOGENIN, a low mobility hyperphosphorylated isoform and a high mobility, hypophosphorylated isoform (Figure 3a, lane 2) . The lower mobility, hyperphosphorylated band is reduced upon pharmacological treatment with AR-A014418 as indicated (Figure 3a, lane 3) . This corresponded with a significant increase in transactivation of an E-box cis element driven reporter gene (Po0.001, Figure 3b ). In contrast, constitutively active GSK3b(S9A) without pharmacological inhibition resulted in an increase in the low mobility, hyperphosphorylated band ( Figure 3a , lane 4) which corresponded to a decrease in E-box luciferase activity in reporter gene assays (Po0.05, Figure 3b ).
Mutation of a consensus GSK3b phosphoacceptor site on MYOGENIN (S160/164A) prevents GSK3b-mediated repression. By in silico analysis, MYOGENIN contains a highly conserved putative GSK3b consensus phosphoacceptor site (Table 1) , which we targeted by neutralizing site-directed mutagenesis. We observed that although wild-type MYOGENIN is sensitive to the repressive effects of constitutively active GSK3b(S9A), MYOGENIN E-box Luc reporter gene was co-transfected in Cos7 cells using the same conditions that were described above. Overexpressed MYOGENIN significantly enhanced transcriptional activity of the E-box promoter (***Po0.001) and, this effect was further increased in the presence of GSK3b inhibitor despite overexpression of GSK3b(S9A) (Po0.001). Overexpression of GSK3b(S9A) repressed MYOGENIN transcriptional activity (**Po0.05) (S160/164A) was not (Figure 4a ). Western blot analysis revealed that MYOGENIN (S160/164A) mutations correspond with a decrease in the low mobility, hyperphosphorylated upper band ( Figure 4b , lane 2) and that this effect was not altered by ectopically expressed HAGSK3b(S9A). Together these data indicate that S160/164A mutations in MYOGENIN render it insensitive to the repressive effect of GSK3b. GSK3b(S9A) expression resulted in an increase in the low mobility, hyperphosphorylated form of wild-type MYOGENIN (Figure 4b , lane 3) and this corresponded with decreased E-box luciferase activity (Po0.001, Figure 4a ). Although trans-activation of the skeletal muscle gene E-box cis-element by mutated MYO-GENIN (S160/164A) is marginally less potent than wild-type MYOGENIN (Po0.05, Figure 4c) ; it is resistant to inhibition by activated GSK3b (Po0.001, Figure 4c ).
PAX3-FOXO1 activation of GSK3b antagonizes muscle creatine kinase promoter activation. To further examine the functional significance of our findings, we used MCK promoter activity, as a key indicator of the activation of myogenic differentiation, in C2C12 myoblasts that were transfected with or without the PAX3-FOXO1 oncogene (Figure 5a ). These data depict that PAX3-FOXO1 represses MCK promoter activation in myoblasts that have been co-transfected with MYOGENIN (Po0.01) and this effect is not only abrogated by pharmacological inhibition of GSK3b, but further activated (Po0.001, Figure 5a ). Interestingly, in PAX3-FOXO1 expressing, human ARMS-derived RH30 cells, ectopically expressed MYOGENIN had no effect on MCK promoter activity unless it was coupled with pharmacological inhibition of GSK3b using AR-A014418 (Po0.001, Figure 5b ). Conversely, mutated MYOGENIN (S160/164A)
Myogenin Myogenin (S160/164A) HA-GSK3β was able to potentiate MCK promoter activity regardless of GSK3b inhibition (Po0.05, Figure 5b ). Taken together, these data provide evidence that S160/164 on MYOGENIN are likely key targets of GSK3b signaling in alveolar rhabdomyosarcoma resulting in a diminution of the critical E-box dependent gene activation that is necessary and sufficient for differentiation.
Manipulation of GSK3b and MYOGENIN activity reduces tumorigenic properties of ARMS-derived RH30 cells.
Colony-formation assays were performed as previously described using RH30 cells 32 which can grow in an anchorage independent manner. Equal numbers of RH30 cells that have been transiently transfected with or without MYOGENIN containing the S160/164A mutations were seeded in growth media with or without 10 mM AR-A014418 (GSK3b inhibitor) and allowed to form colonies for 21 days ( Figure 6 ). The addition of 10 mM AR-A014418 significantly impaired the ability of RH30 cells to form colonies (Po0.05) and remarkably reduced the size of the colonies (Po0.0001). A similar reduction in colony numbers and size were also evident in RH30 cells that were transfected with MYOGENIN (S160/164A) mutations (Figures 6a and b) . In addition, we confirmed that pharmacological inhibition of GSK3b significantly reduced cell proliferation of PAX3-FOXO1 expressing cells (Figure 6c ). Collectively these findings strongly indicate that GSK3b activity promotes the tumorigenicity of RH30 cells and that this effect is neutralized by expression of MYOGENIN bearing mutations that render it insensitive to GSK3b.
Electrical stimulation of ARMS-derived RH30 cells reduces GSK3b activity through Akt (PKB).
Electrical stimulation of skeletal muscle cells in cell culture has been shown to induce phenotype alterations and differentiation. 33 Given that rhabdomyosarcoma shares properties of the skeletal muscle lineage, we electrically stimulated cultured RH30 cells for 4 h/day (5 Hz) for up to 4 days with the idea that it might promote differentiation by affecting the Akt/GSK3b signaling pathway. 34 Stimulation of these cells resulted in an increase in pAktT308 to levels that were 3.00±0.72-fold higher than those in non-stimulated cells after 4 days of stimulation (Figures 7a and b) . Concomitantly, pGSKbS9 was also increased 2.25 ± 0.37 fold following 4 days of stimulation (Figures 7a and c) . These increases in pAktT308 and pGSKbS9 were not a result of increases in total protein (Figure 7a ) as indicated by the 3.76 ± 1.32 and 2.05 ± 0.55 increases in relative phosphorylation, respectively (Figures 7d and e) . These changes in kinase activity corresponded with increased E-box promoter activity in stimulated cells compared with controls (Figure 7f ). Collectively, these data indicate that electrical stimulation suppresses GSK3b activity and correspondingly activates MRF activity supporting our previous findings and also highlighting the possibility of using electrical stimulation as a therapeutic intervention in ARMS patients.
Discussion
ARMS, unlike ERMS, has a well-characterized cytogenetic basis in the majority of patients resulting from chromosomal translocations between chromosomes 1 and 13 and also 2 and 13 that result in fusion of the DNA binding domains of either Pax7 or PAX3 with the trans-activation domain of the Forkhead (FKHR) transcription factor family member Foxo1. 1, 2, 35 In view of the well-substantiated crucial role of PAX3 and 7 in the development of skeletal muscle 4, 5 it is therefore not surprising that the signature of ARMS tumor cells is a muscle-like phenotype and the expression of a variety of structural muscle marker genes such as myosin heavy chain and desmin. 36 What is surprising is the sustained expression of MYOD and MYOGENIN in ARMS, which are transcription factors that are intimately associated with the terminally differentiated, non-proliferative phenotype of normal myogenic cells, begging the question as to why they cannot exert this effect in ARMS. In particular, the function of MYOGENIN in the myogenic regulatory hierarchy places it at a pivotal and required step in the terminal commitment of myogenic progenitors to the differentiation program. 19, 20, 34 Thus, our observations reported here, that MYOGENIN function in ARMS is repressed by inappropriate sustained signaling by the kinase GSK3b, may be of considerable *** Figure 6 Soft agarose colony formation and MTT cell proliferation assays: (a) Equal numbers of RH30 cells were seeded under different conditions as depicted, and allowed to form colonies for 21 days. On the 22nd day the colonies were stained with 0.005% Crystal Violet overnight. Colonies were counted at different planes (n ¼ 10) in four independent experiments done in triplicate. The total number of colonies was reduced by (i) 10 mM AR-A014418, Po0.05 (ii) Transient transfection of MYOGENIN containing the S160/164A neutralizing mutations, Po0.01 and (iii) both, Po0.001. Also see Supplementary Figure 1 for visual representation of the data. (b) We searched for the three largest colonies in each of the 12 plates for each condition and calculated the area using ImageJ software. The data revealed that the control colonies could grow up to 9 Â bigger than any of the experimental conditions, Po0.001. (c) MTT cell proliferation assays were performed in PAX3/FOXO1A-expressing cells with and without 10 mM AR-A014418 treatment. The experiment revealed that GSK3b inhibition reduces cell proliferation by B2-fold, Po0.001. # ns, *Po0.05, **Po0.01, ***Po0.001
GSK3b represses MYOGENIN function in ARMS MG Dionyssiou et al significance for understanding the etiology of this disease. Moreover, as repression of kinase activity is, in many cases, a tractable pharmacologic approach, we now propose targeting GSK3b activity as a tangible therapeutic strategy for ARMS.
In support of the above, a recent study showed that ARMSassociated PAX3/7-Foxo1 fusion proteins inhibit MYOD target genes. 39 It was also reported that forced MYOD/Eprotein dimer expression could not rescue PAX3/7-Foxo1 repression of myogenic factors. 39 Here, we also report that ectopically expressed PAX3-FOXO1 represses the induction of muscle genes, even when MRFs are expressed. We propose that the posttranslational repression of MYOGENIN GSK3b represses MYOGENIN function in ARMS MG Dionyssiou et al activity is due to sustained GSK3b activity and, through a cross-talk mechanism, subsequent repression of p38 MAPK (Supplementary Figure 1) as we have previously described.
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p38 MAPK and PKB/Akt are both required for activation of MEF2/MYOD transcriptional control and chromatin remodeling events at crucial myogenic loci for the differentiation program. 11, 40 In other systems, GSK3b phosphorylation of its protein substrates results in subsequent targeting for proteasomal degradation. 12, 13 However, GSK3b does not appear to affect MYOGENIN protein stability in our experiments as we observe an increase in a slow migrating, hyperphosphorylated form of MYOGENIN in response to GSK3b signaling that is not reduced in terms of its level of expression suggesting that proteasomal degradation of MYOGENIN is not enhanced by GSK3b. Conversely, neutralizing mutations of the GSK3b consensus enhanced MYOGENIN trans-activation of the muscle creatine kinase promoter, and also reduced the tumorigenic properties of ARMS cells (RH30) in a colony-formation assay. These findings suggest that GSK3b-mediated inhibition of MYOGENIN trans-activation properties impairs MYOGENIN's ability to promote terminal differentiation in tumorigenic RH30 cells.
Cell cycle control is an essential component of normal growth control and development which goes awry in tumorigenesis. To date several growth-promoting PAX3-FOXO1 target genes have been implicated in RMS such as the IGF-R and c-Met although, while their contribution to proliferation is likely, the extent of their precise involvement in ARMS is still not clear. 41 During normal skeletal myogenesis, upregulation of a cyclin-dependent kinase inhibitor, p21, stalls myoblasts in the G2/M phase of the cell cycle thus priming them for differentiation by promoting cell cycle exit, which is a requirement for subsequent muscle-specific gene expression. 42 Consistent with the idea that GSK3b activation may contribute to the oncogenic properties resulting from PAX3-FOXO1 expression in ARMS, we observed that the number of proliferative RH30 cells is approximately halved by pharmacological inhibition of GSK3b. So far, the exact mechanism by which GSK3b regulates cell proliferation in ARMS is unknown. However, GSK3b has recently been shown to activate KLF6 43 and we recently identified that KLF6 enhances cell proliferation in myogenic cells through a TGFb/Smad3 dependent pathway. 44 We therefore speculate that PAX3-FOXO1/GSK3b enhancement of cell proliferation may involve KLF6 as a downstream effector as it is also highly expressed in various RMS cell types.
In summary, MYOGENIN normally activates genes that regulate cell fusion and terminal differentiation of skeletal muscle. In PAX3-FOXO1 expressing ARMS cells, our data indicate that sustained GSK3b activity represses MYOGENIN function, contributing to the transformed, proliferative phenotype of these cells. On the basis of this evidence, we propose that pharmacologic targeting of GSK3b kinase activity may constitute a tractable therapeutic strategy for ARMS.
Materials and Methods
Plasmids. E-box, MYOGENIN and MCK reporter constructs in pGL3 and expression vectors for MYOGENIN in EMSV were used in reporter gene assays.
HA-tagged PAX3-FOXO1 was cloned into pcDNA3.1 and kindly donated by Dr. Malkin at MaRS, Toronto. HA-tagged GSK3b(S9A) was cloned in pcDNA3 ORF 995-2305.
Antibodies. Anti-MYOGENIN and anti-HA mouse monoclonal antibodies as well as anti-MEF2A rabbit polyclonal antibody were produced with the assistance of the York University Animal Care Facility; anti-PAX3 (1 : 250; Cell Signaling, Whitby, ON, Canada) GSK3b, phospho-GSK3b (1 : 1000; Cell Signaling); actin, MYOD, Myf-5, GFP, dsRed2 (1 : 2000; SantaCruz, Santa Cruz, CA, USA) were used for immunoblotting experiments.
Cell culture and transfection. C2C12, Cos7 and RH30 cells were maintained in DMEM supplemented with 10% fetal bovine serum (HyClone, Burlington, ON, Canada), 1% L-glutamine and 1% penicillin-streptomycin. Cells were maintained in a humidified, 37 1C incubator with a 5% CO 2 atmosphere. For transfections, cells were seeded 1 day before transfection and transfected according to the standard calcium phosphate method previously described. A mixture of 50 ml 2.5 M CaCl 2 per 25 mg DNA with an equal volume of 2x HeBS (2.8 M NaCl, 15 mM Na 2 HPO 4 , 50 mM HEPES, pH ¼ 7.15) was used and the cells were incubated overnight followed by washing and addition of fresh media. The cells were counted and transferred to pre-gelatin-coated plates.
Protein extractions, immunoblotting and reporter gene assays. Cells were collected using an NP-40 lysis buffer (0.5% NP-40, 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10 mM sodium pyrophosphate, 1 mM EDTA (pH 8.0), 0.1 M NaF) containing 10 mg/ml leupetin and aprotinin, 5 mg/ml pepstatin A, 0.2 mM phenylmethylsulfonyl fluoride and 0.5 mM sodium orthovanadate. Protein concentrations were determined using the Bradford method (Bio-Rad, Mississauga, ON, Canada) with bovine serum albumin (BSA) as a standard. An amount 20 mg of total protein extracts were used for immunoblotting, diluted in sample buffer containing 5% b-mercaptoethanol and boiled.
Transcriptional assays were done using luciferase reporter plasmids. The cells were collected for these assays using 20 mM Tris, (pH 7.4) and 0.1% Triton-X 100 and the values obtained were normalized to b-galactosidase activity expressed from a constitutive SV40 driven expression vector and represented as relative light units (RLU) or in some cases corrected Luciferase values for control, reporter alone transfections were arbitrarily set to 1.0, and fold activation values were calculated. Bars represent the mean (n ¼ 3) and error bars represent the standard error of the mean (n ¼ 3). Independent two sample t-tests of all quantitative data were conducted using R software. P-values are indicated with respect to controls where appropriate.
In vitro kinase assay. A total of 3 mg of purified recombinant GST-MYOGENIN was mixed with either 0.5 mg purified recombinant GST-GSK3b (1-433; Cell Signaling) and with (g-32 P) ATP and incubated for 30 min at 30 1C. Samples were denatured for 5 min at 95 1C in SDS sample buffer. Protein samples were then separated by 10% SDS-PAGE and exposed on X-ray film (Kodak X-Omat, Toronto, ON, Canada) for 21 h to detect 32 P incorporation. The lanes containing GST-MYOGENIN are elongated because two lanes were pooled to fit a higher total reaction volume to accommodate for the low concentration of purified GST-MYOGENIN (0.06 mg/ml). All lanes contain equal total amounts of proteins (3 mg).
Electrical stimulation. Cells were plated onto 0.1% gelatin-coated 6-well plates. The lids of the plates were fitted with two parallel platinum wire electrodes, placed at the opposite ends of each well and extending into the media. The wires from all wells were arranged in parallel and connected to an electrical stimulator (Harvard Apparatus Canada, Saint-Laurent, Quebec, Canada). Cells were stimulated at 5 V and a frequency of 5 Hz for 4 hours/day and allowed a subsequent 20 h recovery period. Cells were collected following the recovery period throughout the 4 days of the protocol.
Soft agarose colony-formation assay. Materials: 0.7% (w/v) DNA grade Agarose, 1% (w/v) DNA grade Agar, 0.005% Crystal Violet (Sigma-Aldrich, Oakville, ON, Canada), 2X Media þ 20% (v/v) FBS. After 48 h of transfection with MYOGENIN containing the S160/164A mutations or empty vector, RH30 cells were assayed for their capacity to form colonies as previously described. 45 A total of 1 Â 10 4 cells were suspended on a layer of 0.35% agarose in DMEM (10% FBS) with or without 10 mM AR-A014418, in 6-well plates. Medium was refreshed every 3-5 days as needed and on the 22nd day, the amount of colonies were counted using a contrast phase microscope. The relative colony sizes were calculated using ImageJ software (Scion Corporation, Frederick, MD, USA). Four independent experiments were carried out in triplicate.
